The team, Life Sciences Private Capital, plans to invest in early- to later-stage healthcare companies and seeks to capitalize on innovation in areas such as genetic medicine, autoimmune diseases, cardiometabolic diseases and rare disorders, according to a Nov. 1 press release from JPMorgan.
A group of advisers will assist the investment team, meeting regularly and providing guidance as needed to help portfolio companies. The advisers are:
- Laurie Glimcher, MD, president and CEO of the Boston-based Dana-Farber Cancer Institute
- Jeffrey Leiden, MD, PhD, executive chair and former CEO of drug developer Vertex Pharmaceuticals
- Frederic Moll, MD, a robotic surgery pioneer and entrepreneur who is now an executive at Johnson & Johnson
- Stephen Oesterle, MD, former senior vice president for medicine and technology at medical-technology company Medtronic
- Robert Stockman, co-founder and former CEO of medical device company REVA Medical
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.